Clinical Trials Browser

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Bronchogenic, Disease, Esophageal Neoplasms, Glioblastoma, Kidney Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

NCT03844750 2025-12-31

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

Phase 2 Terminated

6 enrolled 12 charts

Gastrointestinal

Colorectal Neoplasms

NCT04729322 2025-12-23

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

Phase 2 Active not recruiting

15 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

161 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT05131919 2025-12-09

PUMA

Phase 2 Active not recruiting

25 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT02437071 2025-12-05

Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients

Phase 2 Completed

34 enrolled 10 charts

Gastrointestinal

Colorectal Neoplasms

NCT02512172 2025-12-03

A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer

Phase 1 Completed

27 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03984578 2025-11-18

Window of Opportunity Study in Colorectal Cancer

Phase 2 Completed

33 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06846268 2025-07-25

Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer

Phase 2 Recruiting

20 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03657641 2025-07-04

Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer

Phase 1/2 Active not recruiting

75 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03396926 2025-02-28

Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer

Phase 2 Completed

44 enrolled 15 charts

Gastrointestinal

Colorectal Neoplasms

NCT05167409 2025-01-13

A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer

Phase 2 Active not recruiting

48 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06530303 2024-11-05

BAH248

Phase 1/2 Recruiting

85 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05518032 2024-09-26

Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT03475004 2024-09-19

Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer

Phase 2 Completed

53 enrolled 14 charts

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT05462236 2024-07-09

MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer

Phase 2 Recruiting

120 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05609656 2024-06-03

ELI

Phase 2 Terminated

4 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05746897 2024-01-26

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

Phase 1 Recruiting

38 enrolled

BreastDermatologicGastrointestinalGynecologic

Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05909423 2023-06-18

FLU-IMMUNE

Phase 2 Not yet recruiting

21 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05201612 2023-02-24

PEMBROLA

Phase 2 Unknown

40 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05725200 2023-02-21

EVIDENT

Phase 2 Recruiting

40 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04014530 2023-02-01

ATAPEMBRO

Phase 1/2 Recruiting

47 enrolled

GastrointestinalGynecologic

Neoplasm Metastasis, Colorectal Neoplasms, Endometrial Neoplasms

NCT02713373 2022-10-06

Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery

Phase 1/2 Completed

45 enrolled 14 charts

Gastrointestinal

Colorectal Neoplasms

NCT03274804 2022-06-07

PICCASSO

Phase 1 Completed

20 enrolled 12 charts

Gastrointestinal

Colorectal Neoplasms

NCT03332498 2022-06-03

Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers

Phase 1/2 Completed

40 enrolled 12 charts

Gastrointestinal

Colonic Diseases, Colonic Neoplasms, Colorectal Neoplasms

NCT05333809 2022-04-20

Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer

Phase 2 Unknown

30 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT02375672 2022-02-16

Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer

Phase 2 Completed

30 enrolled 15 charts

Gastrointestinal

Colorectal Neoplasms

NCT04119830 2022-02-08

Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT02851004 2021-09-05

Special Combination of BBI608 and Pembrolizumab

Phase 1/2 Terminated

55 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT02981524 2021-02-10

Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer

Phase 2 Completed

17 enrolled 12 charts

Gastrointestinal

Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Neoplasms, Neoplasms by Site, Rectal Diseases, Colorectal Neoplasms

NCT02757391 2020-10-30

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors

Phase 1 Terminated

1 enrolled

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02318901 2019-10-21

PembroMab

Phase 1/2 Terminated

16 enrolled 6 charts

BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT02260440 2019-09-17

A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer

Phase 2 Completed

31 enrolled 7 charts

Gastrointestinal

Colorectal Neoplasms

NCT03182894 2018-08-28

Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer

Phase 1/2 Withdrawn

Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

Clinical Trials

Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer

IGNITE-CRC

PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

NIVO1002024

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

ARETHUSA

EBNK-ST-001

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

PUMA

Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients

A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer

Window of Opportunity Study in Colorectal Cancer

Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer

Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer

Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer

A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer

BAH248

Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)

Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer

MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer

ELI

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

FLU-IMMUNE

PEMBROLA

EVIDENT

ATAPEMBRO

Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery

PICCASSO

Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers

Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer

Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer

Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer

Special Combination of BBI608 and Pembrolizumab

Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors

PembroMab

A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer

Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer